A novel biomarker-guided immunomodulatory approach for the therapy of sepsis

American Journal of Respiratory and Critical Care Medicine

Volumn 180, Issue 7, 2009, Pages 585-586

  Trapnell, Bruce C ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLACEBO; TOLL LIKE RECEPTOR 2;

ANTIBIOTIC THERAPY; BONE MARROW CELL; CELL FUNCTION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG TOLERABILITY; EDITORIAL; HUMAN; IMMUNE FUNCTION TEST; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INCIDENCE; INFLAMMATION; INTENSIVE CARE UNIT; MONOCYTE; MORTALITY; PRIORITY JOURNAL; SEPSIS; TREATMENT DURATION;

BIOLOGICAL MARKERS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNE TOLERANCE; SEPSIS; SHOCK, SEPTIC;

EID: 70349468020     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200907-1095ED     Document Type: Editorial

References (12)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310. (Pubitemid 32641789)
2. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995;273:117-123.
3. Bone RC. Why sepsis trials fail. JAMA 1996;276:565-566.
4. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997;112:235-243. (Pubitemid 27343624)
5. Adib-Conquy M, Cavaillon JM. Compensatory anti-inflammatory response syndrome. Thromb Haemost 2009;101:36-47.
6. Trapnell B. Granulocyte macrophage-colony stimulating factor augmentation therapy in sepsis: is there a role? Am J Respir Crit Care Med 2002;166:129-132. (Pubitemid 34765443)
7. Uchida K, Beck DC, Yamamoto T, Berclaz PY, Abe S, Staudt MK, Carey BC, Filippi MD, Wert SE, Denson LA, et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 2007;356:567-579. (Pubitemid 46220817)
8. Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003;349:2527-2539.
9. Williams MA, White SA, Miller JJ, Toner C, Withington S, Newland AC, Kelsey SM. Granulocyte-macrophage colony-stimulating factor induces activation and restores respiratory burst activity in monocytes from septic patients. J Infect Dis 1998;177:107-115. (Pubitemid 28030441)
10. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009;180:640-648.
11. Presneill JJ, Harris T, Stewart AG, Cade JF, Wilson JW. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002;166:138-143. (Pubitemid 34765447)
12. Orozco H, Arch J, Medina-Franco H, Pantoja JP, Gonzalez QH, Vilatoba M, Hinojosa C, Vargas-Vorackova F, Sifuentes-Osornio J. Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: A randomized, double-blind, placebo-controlled clinical trial. Arch Surg 2006;141:150-153, discussion 154. (Pubitemid 43276563)